- Nasr SH, Valeri AM, Appel GB, Sherwinter J, Stokes MB, Said SM, Markowitz GS, D'Agati VD, (2009) Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol 4: 22–32 [CrossRef] [PubMed] [Google Scholar]
- Servais A, Noel LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, Macher MA, Zuber J, Karras A, Provot F, Moulin B, Grünfeld JP, Niaudet P, Lesavre P, Frémeaux-Bacchi V, (2012) Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 82: 454–464 [CrossRef] [PubMed] [Google Scholar]
- Servais A, Frémeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B, Grünfeld JP, Lesavre P, Noël LH, Fakhouri F, (2007) Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 44: 193–199 [CrossRef] [PubMed] [Google Scholar]
- Fakhouri F, Frémeaux-Bacchi V, Noel LH, Cook HT, Pickering MC, (2010) C3 glomerulopathy: a new classification. Nat Rev Nephrol 6: 494–499 [CrossRef] [PubMed] [Google Scholar]
- Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Frémeaux-Bacchi V, Gale DP, de Jorge EG, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, Morgan BP, Nast CC, Noel LH, Peters DK, Rodríguez de Córdoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT, (2013) C3 glomerulopathy: consensus report. Kidney Int 84:1079–89 [CrossRef] [PubMed] [Google Scholar]
- Hou J, Markowitz GS, Bomback AS, Appel GB, Herlitz LC, Barry Stokes M, D'Agati VD, (2014) Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int 85: 450–456 [CrossRef] [PubMed] [Google Scholar]
- Bridoux F, Desport E, Frémeaux-Bacchi V, Chong CF, Gombert JM, Lacombe C, Quellard N, Touchard G, (2011) Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephrol 6: 2165–2174 [CrossRef] [PubMed] [Google Scholar]
- Chauvet S, Frémeaux-Bacchi V, Petitprez F, Karras A, Daniel L, Burtey S, Choukroun G, Delmas Y, Guerrot D, François A, Le Quintrec M, Javaugue V, Ribes D, Vrigneaud L, Arnulf B, Goujon JM, Ronco P, Touchard G, Bridoux F, (2016) Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. Blood 129: 1437–1447 [CrossRef] [Google Scholar]
- Zand L, Kattah A, Fervenza FC, Smith RJ, Nasr SH, Zhang Y, Vrana JA, Leung N, Cornell LD, Sethi S, (2013) C3 glomerulonephritis associated with monoclonal gammopathy: a case series. Am J Kidney Dis 62: 506–514 [CrossRef] [PubMed] [Google Scholar]
- Frémeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschênes G, Lebranchu Y, Zuber J, Loirat C, (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8: 554–562 [CrossRef] [PubMed] [Google Scholar]
- Blanc C, Togarsimalemath SK, Chauvet S, Le Quintrec M, Moulin B, Buchler M, Jokiranta TS, Roumenina LT, Frémeaux-Bacchi V, Dragon-Durey MA, (2015) Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases. J Immunol 194: 5129–5138 [CrossRef] [PubMed] [Google Scholar]
- Marinozzi MC, Roumenina LT, Chauvet S, Hertig A, Bertrand D, Olagne J, Frimat M, Ulinski T, Deschênes G, Burtey S, Delahousse M, Moulin B, Legendre C, Frémeaux-Bacchi V, Le Quintrec M, (2017) Anti-Factor B and anti-C3b autoantibodies in C3 glomerulopathy and Ig-associated membranoproliferative GN. J Am Soc Nephrol 28: 1603–1613 [CrossRef] [Google Scholar]
- Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodríguez de Córdoba S, Roumenina LT, Sethi S, Smith RJ; Conference Participants, (2017) Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) controversies conference. Kidney Int 91: 539–551 [CrossRef] [PubMed] [Google Scholar]
- Oosterveld MJ, Garrelfs MR, Hoppe B, Florquin S, Roelofs JJ, van den Heuvel LP, Amann K, Davin JC, Bouts AH, Schriemer PJ, Groothoff JW, (2015) Eculizumab in pediatric sense deposit disease. Clin J Am Soc Nephrol 10: 1773–1782 [CrossRef] [PubMed] [Google Scholar]
- Fakhouri F, de Jorge EG, Brune F, Azam P, Cook HT, Pickering MC, (2010) Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney Int 78: 279–286 [CrossRef] [PubMed] [Google Scholar]
- Rabasco C, Cavero T, Roman E, Rojas-Rivera J, Olea T, Espinosa M, Cabello V, Fernández-Juarez G, González F, Ávila A, Baltar JM, Díaz M, Alegre R, Elías S, Antón M, Frutos MA, Pobes A, Blasco M, Martín F, Bernis C, Macías M, Barroso S, de Lorenzo A, Ariceta G, López-Mendoza M, Rivas B, López-Revuelta K, Campistol JM, Mendizábal S, de Córdoba SR, Praga M; Spanish Group for the Study of Glomerular Diseases (GLOSEN), (2015) Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 88: 1153–1160 [CrossRef] [PubMed] [Google Scholar]
- Le Quintrec M, Lionet A, Kandel C, Bourdon F, Gnemmi V, Colombat M, Goujon JM, Frémeaux-Bacchi V, Fakhouri F, (2015) Eculizumab for treatment of rapidly progressive C3 glomerulopathy. Am J Kidney Dis 65: 484–489 [CrossRef] [PubMed] [Google Scholar]
- Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C, (2017) Haemolytic uraemic syndrome. Lancet 390: 681–696 [CrossRef] [PubMed] [Google Scholar]
- de Jorge EG, Macor P, Paixao-Cavalcante D, Rose KL, Tedesco F, Cook HT, Botto M, Pickering MC, (2011) The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol 22: 137–145 [CrossRef] [Google Scholar]
- Pickering MC, Warren J, Rose KL, Carlucci F, Wang Y, Walport MJ, Cook HT, Botto M, (2006) Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc Natl Acad Sci USA 103: 9649–9654 [CrossRef] [Google Scholar]
- Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, Stokes MB, Markowitz GS, D'Agati VD, Canetta PA, Radhakrishnan J, Appel GB, (2012) Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 7: 748–756 [CrossRef] [PubMed] [Google Scholar]
Accès gratuit
| Numéro |
Méd. Intensive Réa.
Volume 26, Numéro 6, Novembre 2017
Néphrologie et métabolisme
|
|
|---|---|---|
| Page(s) | 456 - 463 | |
| Section | Mise au point / Update | |
| DOI | https://doi.org/10.1007/s13546-017-1311-y | |
| Publié en ligne | 25 octobre 2017 | |
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.